GlassScriptPhysician profile
Lauraine S Jackson
NPI 1336483379
$951.16
in general payments reported to CMS, 2019-2025
15 companies · $543 in 2025
The $543 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $258 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.50 |
| Education | $188.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $387.61 | 2022-2023 | Descovy |
| Regeneron Healthcare Solutions, INC. | $99.26 | 2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $89.00 | 2025 | |
| Genzyme Corporation | $84.41 | 2025 | |
| Verona Pharma, INC. | $52.47 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $34.13 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $34.08 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $27.53 | 2025 | Yupelri |
| Genentech USA, INC. | $25.33 | 2025 | Xolair |
| Glaxosmithkline, LLC. | $23.69 | 2025 | Trelegy Ellipta |
| Philips North America LLC | $21.42 | 2025 | Vest Therapy Und |
| Abbott Laboratories | $20.62 | 2022 | |
| Zoll Respicardia, INC. | $18.30 | 2025 | Remede System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.77 | 2025 | Jascayd |
| Astrazeneca Pharmaceuticals LP | $16.54 | 2025 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauraine Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.